TNFSF13B/BAFF Polyclonal antibody

TNFSF13B/BAFF Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IHC, ELISA

Conjugate

Unconjugated

Cat no : 11862-1-AP

Synonyms

TNFSF13B, CD257, BLYS, B-cell-activating factor, BAFF



Tested Applications

Positive WB detected inU-937 cells, mouse testis tissue, mouse liver tissue, human liver tissue, rat liver tissue
Positive IHC detected inhuman intrahepatic cholangiocarcinoma tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

11862-1-AP targets TNFSF13B/BAFF in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen TNFSF13B/BAFF fusion protein Ag2440
Full Name tumor necrosis factor (ligand) superfamily, member 13b
Calculated Molecular Weight 32 kDa
Observed Molecular Weight 32 kDa, 45-52 kDa
GenBank Accession NumberBC020674
Gene Symbol TNFSF13B
Gene ID (NCBI) 10673
RRIDAB_2303658
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TNFSF13B, also known as BAFF, BLYS, TALL1, TNFSF20, ZTNF4 and CD257, is a cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. This cytokine is expressed in B lineage cells, and acts as a potent B cell activator. The BAFF system promotes B cell survival and differentiation and plays a prominent role in the pathogenesis of autoimmune diseases. It has been shown that BAFF inhibitors are in clinical trials for systemic lupus erythematosus with significant efficacy. This antibody recognizes all the forms of TNFSF13B such as soluble form (17 kDa), membrane form (32-35 kDa) and glycosylation form (45-52 kDa).

Protocols

Product Specific Protocols
WB protocol for TNFSF13B/BAFF antibody 11862-1-APDownload protocol
IHC protocol for TNFSF13B/BAFF antibody 11862-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols